TY - JOUR
T1 - Colorectal cancer pharmacogenomics
AU - Marsh, Sharon
AU - Yu, Jinsheng
AU - Hoskins, Janelle M.
N1 - Funding Information:
The authors are funded in part by the Pharmacogenetics Research Network (U01 GM63340), R21 CA113491, and R21 CA102461.
PY - 2006/12
Y1 - 2006/12
N2 - Colorectal cancer is one of the most common cancer types in both men and women. There are multiple treatment strategies; however, there is currently no clear strategy for therapy selection. Pharmacogenomics includes studies of variations in germline DNA, somatic mutations in the tumor genome, gene amplification, and variations in RNA expression, including epigenetic mechanisms. Pharmacogenomics promises to be a useful tool for identifying markers that can be screened in colorectal patients prior to chemotherapy selection to predict efficacy and/or toxicity. This review highlights some of the ongoing research to identify pharmacogenomic markers in colorectal cancer patients.
AB - Colorectal cancer is one of the most common cancer types in both men and women. There are multiple treatment strategies; however, there is currently no clear strategy for therapy selection. Pharmacogenomics includes studies of variations in germline DNA, somatic mutations in the tumor genome, gene amplification, and variations in RNA expression, including epigenetic mechanisms. Pharmacogenomics promises to be a useful tool for identifying markers that can be screened in colorectal patients prior to chemotherapy selection to predict efficacy and/or toxicity. This review highlights some of the ongoing research to identify pharmacogenomic markers in colorectal cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=41549168878&partnerID=8YFLogxK
U2 - 10.1007/s11888-006-0026-7
DO - 10.1007/s11888-006-0026-7
M3 - Review article
AN - SCOPUS:41549168878
SN - 1556-3790
VL - 2
SP - 217
EP - 224
JO - Current Colorectal Cancer Reports
JF - Current Colorectal Cancer Reports
IS - 4
ER -